Current Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source. 



Research Answers to National Cancer Institute's (NCI) Provocative Questions (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

Application Deadline: June 29, 2018



 
Research Answers to National Cancer Institute's (NCI) Provocative Questions (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

Application  Deadline:  June 29, 2018

Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award: Clinical, Health Services and Policy Research

This Trust was created in 1980 for the advancement of  medical science, particularly research “relating to human diseases,  their causes and relief.” Two-year Awards of $90,000 ($45,000 per year)  will be awarded to Applicants working in Connecticut, New Jersey and  Rhode Island.

Application Deadline: July 3, 2018

Learn more about the Robert E. Leet Mentored Research Award>>

NIH Early-life Factors and Cancer Development Later in Life-R01 

The purpose of this FOA is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. 

Application Deadline: July 5, 2018



NIH Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) 

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research.

Application Deadline: July 5, 2018



Multidisciplinary Studies of HIV/AIDS and Aging R21

These FOAs encourage exploratory/developmental research applications at the intersection of HIV and aging

Application Deadlines: July 5, 2018(R01) July 16, 2018(R21)



Damon Runyon-Rachleff Innovation Award 

Designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. 

Application Deadline: July 6, 2018

DoD Prostate Cancer Research Program Opportunities 

Idea Development Award: This Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. Pre-Application Deadline: July 6, 2018
Impact Award: This Award supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues. Pre-Application Deadline: July 19, 2018
Physician Research Award: This Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. Pre-Application Deadline: August 16, 2018
Early Investigator Research Award : This Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers, under the guidance of one or more designated Mentors. Pre-Application Deadline: August 16, 2018



Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA), encourages research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. The projects should be relevant to adducts in humans and human populations but may be conducted using various model systems (e.g., cultured cells, animals, etc.). The use of human biospecimens is encouraged and expected if appropriate but not required. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. NIEHS may support projects with a focus on innovative technology and method development.  

Application Deadline: July 11, 2018


 
Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA), encourages research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. The projects should be relevant to adducts in humans and human populations but may be conducted using various model systems (e.g., cultured cells, animals, etc.). The use of human biospecimens is encouraged and expected if appropriate but not required. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. NIEHS may support projects with a focus on innovative technology and method development. 

Application Deadline:  July 11, 2018

Learn More>>


DoD Kidney Cancer Research Program Funding Opportunities for 2018

• Concept Award- To support highly innovative, untested, potentially groundbreaking concepts in kidney cancer. Letter of Intent Due: July 11, 2018
• Idea Development Award – To support new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer. Letter of Intent Due: September 5, 2018
• Physicians Research Award – To support a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in kidney cancer research. Letter of Intent Due: September 5, 2018
• Technology Development Award- To support emerging technologies to aid clinical and patient outcomes. Letter of Intent Due: September 5, 2018
• Translational Research Partnership – To support partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications. Letter of Intent Due: September 5, 2018



Bonnie J. Addario Lung Cancer Foundation/Van Auken Private Foundation Young Innovators Team Awards

ALCF, in collaboration with VAPF, is requesting applications from teams of young investigators that address unmet medical needs in lung cancer patient-oriented research. High-risk, high-reward, multidisciplinary, collaborative research projects that are currently unfunded will be awarded $250,000 for a period of 2-3 years (depending on the proposed research). 

Application Deadline: July 15, 2018


Exploratory/Developmental Clinical Research Grants in Obesity- R21

This FOA encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children.

Application Deadline: July 16, 2018



Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries R21

The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS.

Application Deadline: August 1, 2018



HIV/AIDS and the Tumor Niche (R01)

The purpose of this FOA is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or AIDS.

Application Deadline: August 7, 2018



Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (R01/R21)

The purpose of the FOA is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus; the biology of the initial steps of infection; and risk factors for infection in populations living with HIV or at high risk of developing HIV.

Application Deadline: August 18, 2018



NIH Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions-D43

The purpose of this FOA is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country.

Deadline for Application: August 23, 2018

L earn more about Fogarty HIV>>


Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 and R43/R44)

This FOA encourages both (R43/R44) Small Business Innovation Research and (R41/R42) Small Business Technology Transfer grant applications from small business concerns to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings. 

Application Deadline: September 5, 2018

https://grants.nih.gov/grants/guide/pa-files/PAR-18-801.html


"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01/R21)

The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or AIDS. 

Application Deadline: September 7, 2018



HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R01/R21)

The purpose of this FOA is to fill scientific gaps needed to (a) inform HBV functional cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a functional cure in HIV and HBV co-infected individuals.     

Application Deadline: September 7, 2018



In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01/R21)

The purpose of this FOA is to stimulate and accelerate development of novel in vitro and small animal models of HBV/HIV co-infection and create a better understanding of the immunopathogenic interactions between HBV and HIV.   

Application Deadline: September 7, 2018



Harnessing Big Data to Halt HIV (R01)

The purpose of this FOA is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science.

Application Deadline: September 7, 2018



Tobacco Use and HIV in Low and Middle Income Countries (R01)

The purpose of this FOA is to encourage research focused on tobacco use and HIV infection in low and middle income countries.

Application Deadline: November 1, 2018


Defense Health Program: Department of Defense Ovarian Cancer Research Program - Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)


*Although funds have not been appropriated for the FY18 Department of Defense Ovarian Cancer Research Program (OCRP), the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of federal funds appropriated for the OCRP. 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP). The mission of the OCRP is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service members, Veterans, retirees, their family members, and all women impacted by this disease.

Clinical Development Award
• Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
• Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.
• Near-term impact is expected.
• Preclinical studies in animals are not allowed.
• Small-scale clinical trials (Phase 0, Phase 1, Pilot), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed.
• Preliminary data are required.
Optional Nested Early-Career Investigator (ECI): Applications proposing clinical trials and having an ECI that meets the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.
• Submission of a Letter of Intent is required prior to full application submission.
• Maximum funding of $600,000 for direct costs (plus indirect costs).
• With ECI option the maximum funding is $800,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

Letter of Intent Due: July 25, 2018

Omics Consortium Development Award
• Must be an independent investigator at the Associate Professor level or above (or equivalent)
• Supports a multi-institutional research effort conducted by leading cancer researchers and advocates that focuses on the origin of ovarian cancer, with an emphasis on risk stratification, screening and early detection.
• Funds support assembling consortium members and laying the groundwork for the research project, including proof of concept.
• Ovarian cancer advocate(s) are required on the research team.
• Funded applicants will be eligible to compete for the consortium award, which will support the execution of the full research project and is anticipated to be offered in FY20, pending availability of funds.
• Submission of a Letter of Intent is required prior to full application submission
• Maximum funding of $400,000 for direct costs (plus indirect costs).
• Period of performance not to exceed 2 years. 

Letter of Intent Due: July 25, 2018

Investigator-Initiated Research Award
• Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
• Supports meritorious basic and clinically oriented research in ovarian cancer.
• Impact is an important review criterion.
• Preliminary data are required.
• Clinical trials are not allowed.
• Pre-application is required; application is by invitation only.
• Maximum funding of $450,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years. 

Pre-application Due: May 30, 2018

Ovarian Cancer Academy Award – Early-Career Investigator
• Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline. A letter attesting to eligibility is required.
• Supports the addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.
• ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.
• A Designated Mentor may only mentor one ECI candidate.
• The Designated Mentor is not required to be at the same institution as the ECI.
• Preliminary data are required.
• Clinical trials are allowed.
• Submission of a Letter of Intent is required prior to full application submission.
• Maximum funding of $725,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years. 

Letter of Intent: July 25, 2018

Pilot Award
• Investigators at or above the postdoctoral level (or equivalent).
• Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.
• Innovation and Impact are important review criteria.
• Goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.
• Clinical trials are not allowed.
• Pre-application is required and blinded; application submission is by invitation only.
• Maximum funding of $250,000 for direct costs (plus indirect costs).
• Maximum period of performance is 2 years. 

Pre-application Deadline: May 30, 2018

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, go to the CDMRP website (http://cdmrp.army.mil) and select Subscribe to Funding Opportunities & Program Communications. For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process. 

The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants.  


Pew-Stewart Scholars Program for Cancer Research

Yale Cancer Center is pleased to announce the internal competition for the Pew-Stewart Scholars for Cancer Research Program.

The Pew-Stewart Scholars for Cancer Research Program supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer.

Deadline for Applications: June 5, 2018



Gabrielle's Angel Foundation for Cancer Research Grants

The Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood. Funds support promising scientists who are applying novel and state-of-the-art techniques to address fundamental problems in their genesis and treatment.

Internal Deadline: June 11, 2018



Yale Cancer Innovation Awards

YCC is committed to promoting innovative new approaches to cancer treatment and prevention. In collaboration with an anonymous donor, we are proud to announce an empowering new research award program in cancer research.

YCC is requesting individual or team proposals for projects that have direct relevance to cancer research. We seek projects with the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis, or treatment of cancer. Ultimately, we aim to advance proposals that will solve today’s most challenging problems in cancer research and care.

Application Deadline: June 18, 2018

Learn more about the Yale Innovation award>>


P rogram in Innovative Therapeutics for Connecticut's Health (PITCH) 
 
With a grant from the State of Connecticut’s Bioscience Innovation Fund, this three-year, $10 million-dollar program, provides translational research resources to generate prototype therapeutics that address unmet clinical needs. Contact francine.carland@yale.edu for more information. 
 
Application Deadline: July 15, 2018